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Abstract
Background: A fraction of sporadic breast cancers has low BRCA1 expression. BRCA1 mutation carriers are more likely to
achieve a pathological complete response with DNA-damage-based chemotherapy compared to non-mutation carriers.
Furthermore, sporadic ovarian cancer patients with low levels of BRCA1 mRNA have longer survival following platinum-
based chemotherapy than patients with high levels of BRCA1 mRNA.
Methodology/Principal Findings: Tumor biopsies were obtained from 86 breast cancer patients who were candidates for
neoadjuvant chemotherapy, treated with four cycles of neoadjuvant fluorouracil, epirubicin and cyclophosphamide.
Estrogen receptor (ER), progesterone receptor (PR), HER2, cytokeratin 5/6 and vimentin were examined by tissue microarray.
HER2 were also assessed by chromogenic in situ hybridization, and BRCA1 mRNA was analyzed in a subset of 41 patients for
whom sufficient tumor tissue was available by real-time quantitative PCR. Median time to progression was 42 months and
overall survival was 55 months. In the multivariate analysis for time to progression and overall survival for 41 patients in
whom BRCA1 could be assessed, low levels of BRCA1 mRNA, positive PR and negative lymph node involvement predicted a
significantly lower risk of relapse, low levels of BRCA1 mRNA and positive PR were the only variables associated with
significantly longer survival.
Conclusions/Significance: We provide evidence for a major role for BRCA1 mRNA expression as a marker of time to
progression and overall survival in sporadic breast cancers treated with anthracycline-based chemotherapy. These findings
can be useful for customizing chemotherapy.
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Introduction
Breast cancer is the most common cancer in women worldwide,
comprising 23% of all cancers, with more than 1 million new cases
per year[1]. According to the American Cancer Society, breast
cancer death rates have been dropping steadily since 1990 because
of earlier detection and better treatments. Nevertheless, new
strategies are necessary to improve survival of breast cancer
patients, especially in those with advanced disease.
Neoadjuvant chemotherapy is standard therapy for patients with
locally advanced breast cancer and is increasingly used for early-stage
operable disease. The response of breast cancer to neoadjuvant
chemotherapy is correlated with survival [2]; patients who obtain the
greatest survival advantage from neoadjuvant chemotherapy are
those who attain complete response of their primary tumor [3].
Microarray analysis has identified breast cancer subtypes with
distinct gene expression profiles [4,5]. These subtypes have been
correlated with clinical outcome, and the impact of subtype on
response to neoadjuvant chemotherapy has been evaluated in
different series [6]. Easily assessable markers can be used to
approximate breast cancer subtype. Specifically, using the estrogen
receptor (ER), progesterone receptor (PR), and HER2 status of a
tumor, breast subtype can be approximated as follows: luminal A
(ER+ or PR+ and HER2–), luminal B (ER+ or PR+ and HER2+),
HER2+/ER- (ER– and PR– and HER2+), and basal-like (ER– and
PR– and HER2–) [7,8].
Basal-like tumors frequently express ‘basal’ cytokeratins (CKs)
such as CK-5/6, CK-14 and CK-17 [9]. Vimentin expression, a
rather rare occurrence in invasive breast cancer, is associated with
high tumor invasiveness [10] and with in vitro chemosensitivity[11].
Breast cancer susceptibility gene 1 (BRCA1) plays an important
role in DNA repair via transcription-coupled nucleotide excision
repair [12]. BRCA1 encodes a multifactorial protein that is
implicated in DNA repair, cell cycle checkpoint control,
transcriptional regulation, and ubiquitination. BRCA1 methyla-
tion and abrogation of BRCA1 mRNA have been reported in
sporadic breast cancers [13]. Somatic BRCA1 mutations are
rarely observed in sporadic breast cancer; however epigenetic
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downregulation of BRCA1 has been reported in approximately
30% of sporadic breast cancers and 70% of ovarian cancers [14].
BRCA1 expression can modulate cellular response to chemother-
apy. Preclinical breast cancer studies suggest a role for BRCA1 in
predicting response to DNA-damaging agents and taxane-based
chemotherapy. Decreased BRCA1 mRNA expression in breast
cancer cell lines, as determined by real-time quantitative
polymerase chain reaction (RT-QPCR), enhances cisplatin
sensitivity but leads to resistance to paclitaxel and vinorelbine
via defective apoptotic response to these drugs, while the opposite
phenomenon is observed in the presence of normal or high levels
of BRCA1 [15]. In some sporadic breast cancers, the poor
outcome associated with BRCA1 methylation and low expression
levels could be explained by MYC amplification [16]. Further-
more, several retrospective breast cancer studies have confirmed
that carriers of BRCA1 mutations gained more benefit from DNA-
damage-based chemotherapy [17]. Low levels of BRCA1 mRNA
were associated with longer survival in a retrospective cohort of
lung cancer patients following cisplatin gemcitabine [18] and in
two retrospective cohorts of ovarian cancer patients treated with
platinum-based chemotherapy [19]. All these studies suggest that
not only BRCA1 mutations but also reduced expression levels of
BRCA1 mRNA could predict a benefit from DNA-damage-based
chemotherapy. In clinical practice, fresh tumor tissue is not always
available, and the recovery of mRNA from paraffin-embedded
tissue is crucial. RT-QPCR permits quantitative and accurate
measurement of gene mRNA expression [20].
In a retrospective series of 86 breast cancer patients treated with
neoadjuvant fluorouracil, epirubicin and cyclophosphamide (FEC),
we evaluated response, time to progression (TTP) and overall
survival (OS) according to the simplified classification of breast
cancer subtypes based on ER, PR and HER2. In addition, we
examined CK5/6, vimentin and HER2 by immunohistochemistry;
and HER2 by chromogenic in situ hybridization (CISH). Finally, in
41 patients for whom sufficient tumor tissue was available,
intratumoral BRCA1 mRNA levels were assessed by RT-QPCR.
All findings were correlated with response, TTP and OS.
Results
Patient Characteristics
Table 1 shows patient characteristics for all patients (86
patients), for the 41 patients in whom BRCA1 mRNA levels were
Table 1. Patient characteristics.
Entire
Cohort
(N=86) N
(%)
Patients
without
BRCA1
Assessment
(N=45) N
(%)
Patients
with BRCA1
Assessment
(N=41) N
(%) p
Age, median (range) 54 (31–79) 56 (34–74) 55 (31–79) 0.78
Menopausal status 0.51
Premenopausal 36 (42%) 28 (62.2) 22 (54%)
Postmenopausal 50 (58%) 17 (37.8) 19 (46%)
Tumor size (cm) 6 (2.5–12) 6 (2.50–12) 6.4 (2.5–12) 0.34
Tumor differentiation 0.52
Grade I 8 (10.4) 5 (13.2) 3 (7.7)
Grade II 34 (44.2) 18 (47.4) 16 (41)
Grade III 35 (45.5) 15 (39.5) 20 (51.3)
Unknown 9 7 2
Clinical stage 0.51
II 24 (28%) 14 (31.1) 10 (24%)
III 62 (72%) 31 (68.9) 31 (76%)
Pathological response 0.63
Response (G5, G4,
G3)
49 (57%) 27 (60) 22 (53.7%)
No response (G2,
G1)
37 (43%) 18 (40) 19 (46.3%)
Surgery 0.54
Mastectomy 78 (91%) 39 (86.6) 39 (95%)
Lumpectomy 8 (9%) 6 (13.3) 2 (5%)
Pathological nodal
status
0.29
Positive 69 (80%) 34 (75.6) 35 (85%)
Negative 17 (20%) 11 (24.4) 6 (15%)
Histology 0.41
Invasive ductal
carcinoma
79 (92%) 41 (91.1) 38 (93%)
Invasive lobular
carcinoma
5 (6%) 3 (6.7) 2 (5%)
Other: mucinous,
medular
2 (2%) 1 (2.2) 1 (2%)
Estrogen receptor 0.38
0–4% 35 (40.7) 16 (35.6) 19 (46.3)
5–100% 51 (59.3) 29 (64.4) 22 (53.7)
Progesterone
receptor
0.65
0–4% 59 (68.6) 32 (71.1) 27 (65.9)
5–100% 27 (31.4) 13 (28.9) 14 (34.1)
Cytokeratin 5/6* 0.60
Negative 66 (78.6) 35 (81.4) 31 (75.6)
Positive 18 (21.4) 8 (18.6) 10 (24.4)
HER2 by CISH 0.99
Positive 17 (20.2) 9 (20.5) 8 (20)
Negative 67 (79.8) 35 (79.5) 32 (80)
Vimentin* 0.56
Negative 72 (84.7) 37 (82.2) 35 (87.5)
Positive 13 (15.3) 8 (17.8) 5 (12.5)
Subtypes* 0.73
Table 1. Cont.
Entire
Cohort
(N=86) N
(%)
Patients
without
BRCA1
Assessment
(N=45) N
(%)
Patients
with BRCA1
Assessment
(N=41) N
(%) p
HER2+/ER- 11 (13.1) 5 (11.4) 6 (15)
Luminal A 45 (53.6) 25 (56.8) 20 (50)
Luminal B 6 (7.1) 4 (9.1) 2 (5)
Basal-like 22 (26.2) 10 (22.7) 12 (30)
BRCA1 (Median,
range)
---- ---- 16.68 (2.93–
187.40)
----
Clinical characteristics and results of molecular analyses for all 86 patients, for
the 41 patients in whom BRCA1 mRNA expression was assessed and for the 45
in whom BRCA1mRNA was not assessed.
*Technical issues made it impossible to assess some patients.
doi:10.1371/journal.pone.0009499.t001
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assessed, and for the 45 patients in whom BRCA1 mRNA levels
were not assessed. Patient characteristics were similar across the
groups. Median age at diagnosis was 54 years (range, 31-79). Fifty
patients (58%) were postmenopausal. At diagnosis, 24 patients
(28%) were stage II, 62 patients (72%) were stage III. All 86
patients were considered to be candidates for primary therapy
according to the decision of the Breast Cancer Committee of our
institution and were treated with four cycles of FEC. After
chemotherapy, surgery was performed in all 86 patients.
Mastectomy was performed in 78 patients (91%) and lumpectomy
in eight (9%) according to the decision of the Breast Cancer
Committee of each institution. Pathological stages after surgery
were as follows: one patient (1%) was stage 0; eight (9%) were stage
I, 32 (37%) were stage II, 45 (53%) were stage III. At the time of
surgery, 69 patients (80%) had nodal involvement and 17 (20%)
did not. The median number of involved nodes was 3 (range 0-26).
Seventy-nine patients (92%) had ductal carcinoma, five (6%) had
lobular carcinoma and two (2%) had other histologies (mucinous,
medular) (Table 1). ER, PR, CK 5/6, HER2, and Vimentin status
are shown in Table 1. Median follow-up for all patients was 50.5
months (range, 5-154), and median follow-up for alive patients was
77 months (range, 40–154). RT-QPCR and tissue microarray
analyses were performed in the surgical specimens, except for one
patient who presented a pathologic complete response, in whom
analyses were performed in the pretreatment biopsy.
Response, TTP and OS
Pathological response was evaluated according to the Miller and
Payne criteria [21], as shown in Table 2. In one case (1.2%), the
pathological remission was ganglionar and locally complete (G5); in
44 cases (51.2%), there were signs of inflammation, necrosis and
fibrosis with the presence of local infiltrating ductal carcinoma nests
(G4, G3); in 37 cases (43%), no evidence of histological response was
observed (G2, G1). Median TTP was 42 months (95% CI, 21.66–
62.34), and median OS was 55 months (95%CI, 30.09–79.91).
Immunohistochemical Analysis and Outcomes
Based on ER, PR, and HER2 status, 45 patients (52%) were
classified as luminal A, six (7%) as luminal B, 13 (15%) as HER2+/
ER-, and 22 (26%) as basal-like.
CK5/6 were expressed in 18 tumors (21.4%), of which 11
(61.1%) were basal-like, four (22.2%) HER2+/ ER-, two (11.1%)
was luminal A, and one (5.6%) was luminal B. Thirteen tumors
(15.3%) expressed vimentin, of which ten (76.9%) were basal-like,
two (15.4%) were HER2+/ ER-, and one (7.7%) was luminal B.
Since only one patient attained a pathological complete response,
it is impossible to correlate response with any of the potential
markers.
In the univariate analyses for TTP and OS for all 86 patients,
those with ER-negative tumors had a higher risk of relapse (HR,
2.25; p= 0.005) and death (HR, 2.51; p = 0.002) than those with
ER-positive tumors. When patients were grouped according to
subtypes, basal-like patients had the worse prognosis (Table 3). In
the multivariate analyses for TTP and OS, ER-negative was again
identified as a predictive variable (Table 3).
BRCA1 mRNA Expression and Outcomes
Median BRCA1 mRNA expression in the 41 samples assessed
was 16.68 (range, 2.93–187.40). When we compared the results of
the two additional housekeeping genes (r18S, RPLP0) with those
obtained in the original analysis using b-actin, using the Spearman
correlation test (two-sided), a significant correlation among the
three genes was observed: b-actin vs r18S (r=0.70; p,0,001); b-
actin vs RPLP0 (r=0.61; p,0.001); RPLP0 vs r18S (r=0.77;
p,0.001). There was also a significant correlation of BRCA1
expression data calculated according to each of the three
housekeeping genes: BRCA1/b-actin vs BRCA1/b-actin plus
RPLP0 (r=0.60; p,0.001); BRCA1/b-actin vs BRCA1/b-actin
plus r18S (r=0.70; p,0,001) (Supplementary Table S1).
There were no differences in patient characteristics according to
BRCA1 mRNA levels (Table 4). Only one patient attained a
pathological complete response (in tumor but not in axilla); it is
thus impossible to correlate response with BRCA1 mRNA levels.
Low levels of BRCA1 mRNA were associated with better TTP (84
months versus 14 and 36 months; p = 0.009) (Figure 1). Median
OS was not reached in patients with low levels of BRCA1 mRNA,
while it was 21 months for those with intermediate and 50 months
for those with high levels (p = 0.03) (Figure 2).
In the univariate analysis for TTP and OS for these 41 patients,
low levels of BRCA1 mRNA were associated with a lower risk of
Table 2. Patient Characteristics.
Entire Cohort Patients with BRCA1 Assesment
(N=86) (N=41)
RESPONSE Local Axilla* Local + Axilla Local Axilla+ Local + Axilla
CR G5 5 (5.8%) D 1 (1.2%) 1 (2.5%) C 1 (2.4%)
C 4 (4.7%)
PR G4+G3 44 (51.2%) D 6 (6.9%) 21 (51.2%) D 2 (4.9%)
C+B 32 (37.2%) C+B 16 (39.0%)
NO RESPONSE
G1+G2 37 (43%) C+B 33 (38.4%) 19 (46.3%) D 1 (2.4%)
C+B 18 (44%)
Detailed pathologic response for the entire cohort and for the patients with BRCA1 assessment, according to the Miller and Payne criteria.
CR = complete response; PR = partial response. Pathologic response assessment according to the Miller and Payne classification. G5: absence of residual infiltrating
tumour cells. G4: marked disappearance of invasive tumor cells, only small clusters of widely dispersed cells could be detected. G3: considerable reduction in tumor
cells. G2: mild loss of invasive tumor cells, but overall cellularity still high. G1: no reduction in overall numbers as compared with pre-treatment biopsy. B: lymph node
positive with malignant cells. C: lymph node still positive, but with evidence of some regression. D: lymph node previously positive, now without metastases.
*In a total of 10 patientes (11.6%) axilla lymphadenectomy was negative but was also clinically negative before surgery (6 response and 4 no response).
+In a total of 3 patientes (7.3%) axilla lymphadenectomy was negative but was also clinically negative before surgery (2 response and 1 no response).
doi:10.1371/journal.pone.0009499.t002
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relapse and longer survival (p = 0.004 and p= 0.01, respectively),
and positive nodal status was associated with shorter TTP
(p = 0.005) (Table 3). In the multivariate analysis for TTP and
OS, low levels of BRCA1 mRNA, PR+, and negative lymph node
involvement predicted a lower risk of relapse, while low levels of
BRCA1 mRNA and PR+ were the only variables associated with
significantly better survival (Table 5).
Discussion
Patients were treated with a schedule of only four cycles of
anthracyclines before surgery, which was standard practice at the
time of the study, before taxanes were introduced in the primary
treatment setting; this could explain the relatively low rate of
pathological complete responses (1.2%) and conservative surgery
(8%). Current schedules of neoadjuvant chemotherapy, with six to
eight cycles of sequential chemotherapy with anthracyclines and
taxanes, attain an improved rate of pathological complete
responses (20–30%) and conservative surgery (61–67%) [22,23].
Similarly to findings by Sorlie et al [5], in our series, patients
with luminal A tumors attained better TTP and OS than those
with basal-like tumors. In the multivariate analysis including all 86
patients, ER emerged as the strongest predictor of TTP and OS.
Vimentin expression is associated with high tumor invasiveness; in
our cohort, vimentin expression was found only in basal-like and
in HER2+/ER- tumors.
In the multivariate analysis of the subset of 41 patients, BRCA1
mRNA expression level emerged as the strongest predictor of
survival. BRCA1 plays a crucial role in DNA repair and decreased
BRCA1 mRNA has been observed in both sporadic and
hereditary breast cancer. BRCA1 mRNA is reduced in sporadic
breast cancer cells despite the absence of mutations. This
reduction of BRCA1 mRNA levels in sporadic breast cancer
cases has been related to acquired methylation of the BRCA1
promoter [24] and to abnormalities in the upstream pathways that
regulate BRCA1 expression[25].
BRCA1 encodes a nuclear cell cycle regulated protein expressed
in S and G2 phases, which may be why BRCA1 overexpression
Table 3. Univariate analyses for time to progression and overall survival for all 86 patients and for 41 patients in whom BRCA1 was
assessed.
All Patients (N=86) Patients with BRCA1 Assessment (N=41)
Time to Progression Overall Survival Time to Progression Overall Survival
N HR (95% CI) P HR (95% CI) P N HR (95% CI) P HR (95% CI) p
BRCA1 by terciles
Low 14 1 1
Intermediate --- --- --- --- --- 14 4.55 (1.61–12.85) 0.004 3.90 (1.34–11.38) 0.01
High 13 2.42 (0.87–6.76) 0.09 2.41 (0.82–7.09) 0.11
Estrogen receptor
Negative 35 2.25 (1.28–3.95) 0.005 2.51 (1.41–4.47) 0.002 19 1.57 (0.73–3.36) 0.25 1.70 (0.78–3.69) 0.18
Positive 51 1 1 22 1 1
Progesterone receptor
Negative 59 1.40 (0.76–2.58) 0.28 1.74 (0.90–3.36) 0.10 27 1.80 (0.77–4.19) 0.17 1.98 (0.83–4.74) 0.13
Positive 27 1 1 14 1 1
HER2 by CISH 0.30
Negative 67 1 0.35 1 0.22 32 1 0.34 1
Positive 17 1.38 (0.70–2.71) 1.53 (0.78–3.03) 8 1.57 (0.62–3.96) 1.63 (0.65–4.12)
Nodal status
Negative 17 1 0.06 1 0.11 6 1 0.05 1 0.19
Positive 69 2.25 (0.95–5.28) 2.03 (0.86–4.78) 35 7.52 (0.99–56.75) 2.61 (0.61–11.15)
Vimentin
Negative 72 1.26 (0.54–2.97) 0.59 1.01 (0.45–2.23) 0.99 35 1.13 (0.34–3.77) 0.85 0.65 (0.22–1.88) 0.42
Positive 13 1 1 5 1 1
Cytokeratin 5/6
Negative 66 1.06 (0.51–2.18) 0.88 0.83 (0.41–1.67) 0.59 31 1.28 (0.48–3.39) 0.62 0.90 (0.36–2.26) 0.83
Positive 18 1 1 10 1 1
Subtypes
HER2+/ER- 11 0.73 (0.30–1.79) 0.49 0.92 (0.38–2.26) 0.86 6 0.88 (0.26–2.95) 0.84 0.97 (0.30–3.18) 0.96
Luminal A 45 0.39 (0.20–0.75) 0.005 0.38 (0.19–0.74) 0.005 20 0.56 (0.23–1.38) 0.21 0.54 (0.22–1.34) 0.18
Luminal B 6 0.74 (0.25–2.21) 0.59 0.69 (0.23–2.06) 0.50 2 2.07 (0.43–10.05) 0.37 1.65 (0.35–7.82) 0.53
Basal-like 22 1 1 12 1 1
Age 86 1.02 (0.99–1.04) 0.23 1.01 (0.99–1.04) 0.29 41 1.02 (0.99–1.05) 0.28 1.01 (0.98–1.05) 0.38
doi:10.1371/journal.pone.0009499.t003
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has been associated with poor survival in chemonaive
NSCLC[26]. In sporadic breast cancer, absent or reduced BRCA1
expression was associated with high tumor grade, advanced lymph
node stage, larger size, vascular invasion, negative estrogen
receptor, negative progesterone receptor and poor outcome[27].
BRCA1 plays a multifunctional role and has been implicated in
many normal cellular functions, including DNA damage response,
transcriptional regulation, cell-cycle checkpoint control, and
ubiquitination. Consequently, the presence or absence of func-
tional BRCA1 could have a significant effect on cellular response
to chemotherapy and may also have a predictive value,
particularly in patients treated with DNA-damaging agents, as
was the case in the present study.
Preclinical data suggest that BRCA1 can regulate differential
sensitivity to chemotherapeutic agents; the absence of BRCA1
results in increased sensitivity to DNA-damage-based chemother-
apy, while the presence of BRCA1 increases sensitivity to
antimicrotubule agents. It was initially reported that BRCA1
overexpression in human breast cancer cell lines resulted in
increased resistance to DNA-damaging chemotherapy [28,29,30].
In HCC1937 cells, restoring BRCA1 abrogated sensitivity to
apoptosis in the presence of DNA-damaging agents, including
cisplatin and etoposide, while inducing sensitivity to the anti-
microtubule agents paclitaxel and vinorelbine, suggesting that
BRCA1 acts as a differential modulator of apoptosis depending on
the nature of the cellular insult [31]. In a recent report,
Table 4. Patient characteristics in 41 patients according to BRCA1 mRNA levels by terciles.
Low BRCA1 Intermediate BRCA1 High BRCA1 p
N (%) N (%) N (%)
Age, median (range) 59 (45–73) 51 (32–79) 54 (31–74) 0.25
Menopausal status 0.52
Premenopausal 5 (26.3) 8 (42.1) 6 (31.6)
Postmenopausal 9 (40.9) 6 (27.3) 7 (31.8)
Tumor size (cm) 6 (4–10) 7 (2.50–12) 6 (4–11) 0.60
Tumor differentiation 0.56
Grade I 0 2 (14.3) 1 (8.3)
Grade II 6 (46.2) 4 (28.6) 6 (50)
Grade III 7 (53.8) 8 (57.1) 5 (41.7)
Pathological Response 0.26
Response (G5, G4, G3) 10 (45.5) 6 (27.3) 6 (27.3)
No response (G2, G1) 4 (21.1) 8 (42.1) 7 (36.8)
Pathological Nodal status 0.99
Negative 2 (33.3) 2 (33.3) 2 (33.3)
Positive 12 (34.3) 12 (34.3) 11 (31.4)
Cytokeratin 5/6 0.10
Negative 11 (35.5) 8 (25.8) 12 (38.7)
Positive 3 (30) 6 (60) 1 (10)
HER2 by CISH 0.43
Positive 3 (37.5) 4 (50) 1 (12.5)
Negative 11 (34.4) 10 (31.3) 11 (34.4)
Estrogen receptor 0.79
Negative (0–4%) 7 (36.8) 7 (36.8) 5 (26.3)
Positive (5–100%) 7 (31.8) 7 (31.8) 8 (36.4)
Progesterone receptor 0.18
Negative (0–4%) 10 (37) 11 (40.7) 6 (22.2)
Positive (5–100%) 4 (28.6) 3 (21.4) 7 (50)
Vimentin 0.74
Negative 13 (37.1) 12 (34.3) 10 (28.6)
Positive 1 (20) 2 (40) 2 (40)
Subtypes 0.43
HER2+/ER- 3 (50) 2 (33.3) 1 (16.7)
Luminal A 7 (35) 5 (25) 8 (40)
Luminal B 0 2 (100) 0
Basal-like 4 (33.3) 5 (41.7) 3 (25)
doi:10.1371/journal.pone.0009499.t004
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overexpression of BRCA1 and other genes (p53, p21, GST,
MDR1 and TOPOIIa) have been associated with acquired
resistance to doxorubicin in breast cancer cell lines [32].
A differential modulating effect for BRCA1 mRNA expression
was also observed in tumor cells isolated from malignant effusions
of non-small-cell lung cancer and gastric cancer patients, whose
BRCA1 mRNA levels correlated negatively with cisplatin
sensitivity and positively with docetaxel sensitivity [33]. In
addition, several clinical studies have shown a better clinical
response to anthracycline- and cyclophosphamide- containing
regimens in BRCA1 mutation carriers than in sporadic breast
cancer patients [17]. Upregulation of DNA repair genes has been
related to resistance to radiotherapy, and BRCA1 mutation
carriers are more sensitive to radiotherapy [34].
In sporadic breast cancer cases, there is conflicting evidence as
to whether tumors with epigenetic inactivation of BRCA1 will also
obtain greater benefit from DNA-damage-based chemotherapy. In
a study of 51 sporadic breast cancer patients, those with high levels
of BRCA1 attained better response to anthracycline-based
chemotherapy, though overall survival was not examined [34].
This result is in contrast with results from in vitro models, BRCA1
mutated breast cancers, and our results in the present study.
In a retrospective cohort of 70 sporadic epithelial ovarian
cancer patients treated with platinum-based chemotherapy, those
with low levels of BRCA1 mRNA expression had a significantly
improved survival in comparison with those with high levels [35].
Furthermore, BRCA1 mRNA expression levels predicted outcome
following cisplatin-containing chemotherapy in non-small-cell lung
cancer [18]. Along the same lines, in a retrospective study of
locally advanced bladder cancer patients treated with cisplatin-
based chemotherapy, those with low or intermediate levels of
BRCA1 mRNA attained significantly better response, disease-free
survival and OS than those with high levels[36].
In a recent series of 102 non-small-cell lung cancer patients, high
levels of BRCA1 mRNA were associated with better response and
decreased risk of progression to gemcitabine plus docetaxel [37]. Our
findings are consistent with this clinical evidence and with other
clinical studies in breast cancer. In a study comparing BRCA1 germ-
line mutation carriers and non-carriers, response rates to neoadju-
vant docetaxel treatment in the carrier group was limited while non-
carriers attained a high number of complete or partial responses [38].
All these data suggest that BRCA1 plays an important role in cellular
response to chemotherapy, not only to DNA damaging agents but
also to antimicrotubules. In fact, in a recent study in which patients
Figure 1. Time to progression according to BRCA1 mRNA levels.
doi:10.1371/journal.pone.0009499.g001
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with low BRCA1 mRNA levels were treated with cisplatin and
gemcitabine, those with intermediate levels were treated with
cisplatin and docetaxel, and patients with high levels were treated
with docetaxel alone, this BRCA1-customized chemotherapy was
associated with excellent 2-year survival for patients with metastatic
non-squamous cell lung carcinoma[39].
We provide clinical evidence in 41 patients for the role of post-
treatment BRCA1 mRNA levels as a marker of TTP and OS in in
sporadic breast cancer patients treated with anthacyclines.
Although our findings should be interpreted with caution due to
the small number of patients and the retrospective nature of the
study, they warrant further examination in prospective clinical
trials including pre-treatment BRCA1 assessment. Our data
suggest that sporadic breast cancer patients with low levels of
BRCA1 mRNA expression may obtain the greatest benefit from
anthracycline-based therapy.
Materials and Methods
Patients
We collected tumor biopsies from 86 patients diagnosed with stage
II and stage III breast cancer who were who were not eligible for
Table 5. Multivariate analyses for time to progression and
overall survival in 41 patients with BRCA assessment.
Time to Progression Overall Survival
N HR (95% CI) P HR (95% CI) P
BRCA1 by terciles
Low 14 1 1
Intermediate 14 7.68 (2.41–24.55) 0.001 4.52 (1.51–13.46) 0.007
High 13 4.52 (1.50–13.63) 0.007 2.94 (0.99–8.71) 0.05
Progesterone
receptor
Negative 27 4.15 (1.61–10.69) 0.003 2.43 (0.99–5.93) 0.05
Positive 14 1 1
Nodal Status --------
Negative 6 1 0.02
Positive 35 12.01 (1.51–95.16)
doi:10.1371/journal.pone.0009499.t005
Figure 2. Overall survival according to BRCA1 mRNA levels.
doi:10.1371/journal.pone.0009499.g002
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conservative breast treatment and were considered to be candidates
for primary therapy according to the decision of the Breast Cancer
Committee of our institution between 1993 and 2003. The study was
approved by the Ethics Committee of our institution. Signed
informed consent for future biological studies of tumor biopsies was
obtained from all patients. All patients received four cycles of FEC
before surgery. After surgery, patients were evaluated and received
four additional cycles of the same schedule if they had no nodal
involvement and six if they had nodal involvement. If the tumor was
ER- or PR-positive, they received hormonotherapy after completion
of chemotherapy. Patients undergoing lumpectomy also received
breast radiotherapy, and regional nodal radiation was delivered at
the discretion of the breast committee. Samples were collected and
evaluated at the Catalan Institute of Oncology (Badalona, Barcelona,
Spain). Pathological response was evaluated according to the Miller
and Payne criteria [21]. Patients without residual infiltrating cancer
in the breast and axilla were considered to have had a pathological
complete response.
Immunohistochemical Analysis
Breast cancer tissue microarrays were selected based on the
availability of paraffin blocks and prepared by extracting two 1-
mm diameter cores of histological confirmed invasive breast
carcinoma and immunohistochemically stained for ER, PR, basal
cytokeratins HER2, CK5/6 and vimentin. Two cores were
evaluated from each tumor. Each core was scored individually,
and the mean of the two readings was calculated.
ER and PR were considered positive only if nuclear positivity
was seen in more than 5% of neoplastic cells. HER2 staining was
scored according to the criteria specified by DAKO for the
interpretation of the HercepTest. Immunoreaction was deter-
mined to be strongly positive (3+) if a strong complete membrane
staining was observed in more than 10% of neoplastic cells or to be
weakly positive (2+) if more than 10% of the tumor cells showed
weak to moderate complete membrane staining. All other staining
patterns were interpreted as negative (0/1+). Chromogenic in situ
hybridization (CISH) was performed on HER2 immunopositive
cases (2+ or 3+) using a microscope (Leica DMLS2) equipped with
10X, 20X, 40X and 63X dry objectives, with 10x oculars. The
revised standard described by Tanner et al [40], was used to
interpret CISH results.
CK 5/6 and vimentin staining results were assessed using a
three-point scoring system, where 0 was no staining, 1 was weak
staining intensity and/or less than 20% of tumor cells stained, and
2 was strong staining in more than 20% of tumor cells.
BRCA1mRNA Expression
Intratumoral BRCA1 mRNA expression levels were assessed by
RT-QPCR in 41 patients for whom sufficient tumor tissue was
available (Fig. 3). Total RNA was extracted from paraffin-
embedded tumor tissue after laser-capture microdissection that
ensured a minimum of 90% of tumor cells. After deparaffinization
with standard xylene and alcohol process, samples were subjected
to lysis in a buffer containing tris-chloride, EDTA, sodium dodecyl
sulphate, and proteinase K. RNA was then extracted with phenol-
chlorophorm-isoamyl alcohol followed by precipitation with
isopropanolol in the presence of glycogen and sodium acetate.
RNA was resuspended in DEPC water (Ambion Inc., Austin, TX)
and treated with DNAse I to avoid DNA contamination. cDNA
was synthesized using M-MLV retrotranscriptase enzyme. Tem-
plate cDNA was added to TaqMan Universal Master Mix in a
12.5-mL reaction with specific primers and probe for each gene.
The endogenous reference gene was b-actin. Gene expression was
quantified by using the ABI Prism 7900HT Sequence Detection
System (Applied Biosystems)[18]. In order to preclude any
potential false results due to variation in RNA quality in
paraffin-embedded samples and also to validate the robustness of
b-actin as a single housekeeping gene, in a subgroup of 34 patients
for whom RNA was available, BRCA1 expression data was also
calculated according to the median values of b-actin plus RPLP0
and b-actin plus ribosomal 18S as housekeeping genes.
Statistical Analyses
Median values and ranges were derived for quantitative
variables and mRNA gene expression. Qualitative variables were
summarized by means of absolute frequencies and percentages. In
order to provide an easily interpretable evaluation of the effect of
BRCA1 mRNA expression, gene expression values were divided
into terciles.
TTP was calculated from the time of inclusion in the study until
disease progression. Overall survival was estimated from the time
of inclusion until death from any cause. TTP and OS were
calculated using Kaplan-Meier estimates and differences between
curves were tested using the log-rank test. The Cox proportional
hazards method with hazard ratios and 95% confidence intervals
(CIs) were used to fit both univariate and multivariate models,
where stepwise procedure (both forward and backward) were used
to evaluate the independent significance of different variables in
TTP and OS. Analyses were performed using Statistical Package
for the Social Sciences (SPSS) for Windows version 17 (SPSS Inc,
Chicago, IL) and S-Plus 6.1 for Windows.
Supporting Information
Table S1 RNA for additional analyses was available in 34 of the
original 41 samples, and BRCA1 gene expression was assessed in
these 34 samples using two additional housekeeping genes,
ribosomal 18S (r18s) and RPLP0. A significant correlation among
the three genes was observed (p,0.001). Data from real-time
QPCR is shown here.
Found at: doi:10.1371/journal.pone.0009499.s001 (0.08 MB
DOC)
Figure 3. Flow chart of patients. Of 86 patients originally included,
only 41 had sufficient tumor tissue to perform BRCA1 mRNA
assessment.
doi:10.1371/journal.pone.0009499.g003
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